Diffusion Pharmaceuticals Inc. Aktie News

Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway through Phase 2b clinical data which is expected during 2H 2024 BOSTON , Aug. 16, 2023 /PRNewswire/...

LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting

CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today sent a letter to its stockholders. The letter highlights the strength, experience and quality of the Company's boa...

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process

•  Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 •  Reported Positive Effects in TSC Altitude Trial •  Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities •  Expected Cash Runway into First Quarter of 2024

CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies to enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that after collaboration with the United States Food and Drug Administration (“FDA”) on the design of their Ph...

CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced positive effects from its second Oxygenation Trial, the Altitude Trial.